Printer Friendly

Nesfatin-1/Nucleobindin-2 Is a Potent Prognostic Marker and Enhances Cell Proliferation, Migration, and Invasion in Bladder Cancer.

1. Introduction

Bladder cancer (BC) requires an expensive treatment in all cancers and is the second most common urological malignancy [1], which ranks 9th in all cancers [2]. Bladder cancer caused 165,000 deaths in 2012 in developing countries of the world [3]. Estimated 79,030 new cases of bladder cancer occurred in the United States during 2017, and 16,870 patients died because of bladder cancer [4]. In America, there were estimated 81,190 cases of bladder cancer in 2018 and 17,240 cases of deaths [5]. Therefore, bladder cancer causes a great medical burden [6]. The time of diagnosis plays an essential role in the good quality of life and life-long surveillance [7]. Although some new drugs and treatments have increased the survival rate of bladder cancer patients, they are still limited by their side effects.

Nucleobindin-2 (NUCB2) was discovered in 2006 and firstly reported to regulate energy homeostasis and food intake [8, 9]. NUCB2 is a precursor protein of nesfatin-1 [10]. NUCB2 has some functional domains, such as signal peptide, Leu/Ile-rich region [11], two [Ca.sup.2+]-binding EF-hand domains [12], and leucine zipper [13]. NUCB2 is expressed in many tissues and performed a variety of physiological functions, such as anti-inflammation [14,15], reducing cardiovascular risk [16, 17] and atherosclerosis extent [18]. Recently, NUCB2 has also been declared to play a role in proliferation, invasion, and migration in tumor cells and to affect the prognosis of tumor patients [19]. In breast cancer, NUCB2 is a critical prognostic factor [20]. High expression level of NUCB2 represents an independent negative prognostic factor in clear cell renal cell carcinoma (ccRCC) [21]. In prostate cancer [22, 23], gastric cancer [24], colon cancer [25], breast carcinoma [19, 20], and endometrial carcinoma [26], high expression of NUCB2 was linked to poor prognosis due to the enhancement in cell proliferation and migration. However, stimulation with NUCB2 promoted apoptosis in the adrenocortical carcinoma cell (H295R) [27]. Those results suggest that expression of NUCB2 exhibited tissue-specific expression.

In this research, we observed that high expression of NUCB2 was associated with poor prognosis by analyzing immunohistochemistry and information of patients with bladder cancer. Then, knocking down NUCB2 decreased proliferation, migration, and invasion in T24 and 5637 cells which are derived from human bladder cancer cells. Suppression of NUCB2 in T24 cells inhibited tumor growth and metastasis in a nude mouse.

2. Results

2.1. High Expression of NUCB2 Was Associated with Poor Prognosis. To identify whether NUCB2 expression level was associated with prognosis of patients, information of 115 patients was collected including the essential information (Table 1), tumor status, and paraffin sections. The relationship of expression of NUCB2 and prognosis was analyzed by immunohistochemistry. As shown in Figures 1(b) and 1(c), patients with high expression of NUCB2 had a low overall survival rate (OS) and progression-free survival rate (PFS) and high metastasis and vascular invasion. Those data suggested that NUCB2 played an important role in metastasis and invasion in bladder cancer.

2.2. NUCB2 Knockdown by Short Hairpin RNA (shRNA) in T24 and 5637 Cells of Bladder Cancer. Firstly, in order to observe functions of NUCB2 in bladder cancer, T24 and 5637 cells were transfected with specific shRNA to knockdown NUCB2. The total RNA was isolated from cells to observe the expression of NUCB2 using PCR. As shown in Figure 2(a), expression level of NUCB2 was low when transfected with shRNA. Control cells were transfected with vacant plasmid. Then, we tested the protein level of NUCB2 using Western blotting. The results were similar to RNA level (Figure 2(b)). T24 and 5637 cells transfected with shRNA were selected with puromycin until cells formed a stable clone.

2.3. NUCB2 Knockdown Inhibited Cell Proliferation in T24 and 5637 Cells. The cell proliferation assay was firstly introduced to observe the effect of NUCB2 on bladder cancer cell lines when transfected with shRNA. To investigate the effect of NUCB2 on bladder cancer cells in vitro, colony formation assays were introduced. Transfection with NUCB2 shRNA inhibits proliferation (Figure 3(a)) with respect to the control cells. As shown in Figure 3(b), the result of MTT assays was similar to that of colony formation assays. Ki67 and PCNA are markers that indicate cell proliferation. Ki67 and PCNA had lower expression in T24 when transfected with NUCB2 shRNA, and 5637 cells had a similar result (Figures 3(c) and 3(d)). Those data showed that NUCB2 influenced the proliferation in T24 and 5637 cells.

2.4. NUCB2 Effected Migration and Invasion through the MMP2 and MMP9 Pathway. The scratch wound assay was introduced to study cell migration. As shown in Figure 4(a), T24 and 5637 cells transfected with shRNA significantly inhibited migration. Then, the transwell assay was introduced to detect cell invasion. After culturing in chambers for 24 hours, cells with normal expression of NUCB2 had a strong invasion ability (Figure 4(b)). Because the matrix metalloproteinase family plays a crucial role in the migration of cancer cells, we investigated whether NUCB2 regulated migration dependent on MMP2 and MMP9. Western blot was introduced to detect the expression of MMP2 and MMP9. We observed that MMP2 and MMP9 had lower expression when cell lines were transfected with NUCB2 shRNA (Figures 4(c) and 4(d)). Those indicated that NUCB2 effected migration in bladder cancer cells by MMP2 and MMP9.

2.5. Suppression of NUCB2 Inhibited Tumor Growth and Metastasis In Vivo. To investigate functions of NUCB2 in vivo, T24 and shT24 transfected with NUCB2 shRNA in T24 cells were injected into BALB/c mice subcutaneously, respectively. Tumors were measured every 7 days, and all tumors were stripped after 49 days. As shown in Figure 5(a), the tumor growth in vivo of T24 xenografts transfected with shRNA was clearly impaired. In addition, there is some metastatic tumor in the lungs of mice, and tumor volume was reduced when NUCB2 is suppressed (Figure 5(b)). Then, the expression of NUCB2 in tumors and metastatic tumors in mice was investigated using Western blot. The protein expression level of NUCB2 in carcinoma was lower than that in the control group (Figure 5(c)). Those results demonstrated that NUCB2 is a positive regulator of bladder cancer progression.

3. Methods and Material

3.1. Sample Collection. One hundred and fifteen adult patients with bladder cancer were gathered from Tianjin First Center Hospital. These cases were collected based on a clear pathological diagnosis. Informed consent was collected from each patient.

3.2. Immunohistochemistry. The expression of NUCB2 was detected by a rabbit-anti-NUCB2 antibody (Abcam, USA) in paraffin tumor. Detailed experimental steps were completed using the immunohistochemistry kit (Proteintech, USA). Briefly, paraffin sections (4 [micro]m) were put into a microwave oven to repair antigens for 15 min and then were cooled at room temperature. Then, endogenous peroxidase was blocked, and sections were incubated with an anti-NUCB2 antibody overnight at 4[degrees]C and then goat anti-rabbit antibody-HRP at 37[degrees]C for 1 hour. Sections were colored with 3,3-diaminobenzidin (DAB) at room temperature for 10 min. Those images were collected using a microscope (Olympus BX43). All samples were evaluated by two independent pathologists.

For the results, NUCB2 nuclear staining was scored by using 4-point scales (0, no staining; 1+, light staining at high magnification; 2+, intermediate staining; and 3+, dark staining of the linear membrane at low magnification). According to the distribution of scores, NUCB2 was divided into high-expression (2-3+) and low-expression (0-1+) groups, respectively.

3.3. RNA Isolation and PCR. Total RNA was isolated from cancer cells using the TRIzol reagent (Invitrogen). Complementary DNA (cDNA) synthesis was performed using the PrimeScript RT Reagent Kit (Clontech).

The following primers were used: NUCB2 (forward primer: 5'-GAGTCAACGGATTTGGTCGT-3' and reverse primer: 5'-TTGATTTTGGAGGGATCTCG-3') and human [beta]-actin (forward primer: 5'-AGGCACCAGGGCGTGAT-3' and reverse primer: 5'-TCGTCCCAGTTGGTGACGAT-3') [28].

3.4. Western Blotting. Total proteins were collected from T24 and 5637 cells using RIPA and RMSF (100:1) on ice and then quantified by the BCA assay, separated on 10% PAGE gels, and transferred to the PVDF membrane (Millipore, USA). PVDF was washed three times using PBST and blocked with 10% nonfat milk for 1 hour and then incubated with a primary antibody at 4[degrees]C overnight. After being washed three times, PVDF was incubated with a secondary antibody for 1 hour at room temperature and then washed again. Finally, the ECL substrate reagent kit (GE Healthcare, USA) was used to collect protein bands on the imaging capture system (Alpha Innovation).

3.5. Cell Culture. The bladder cancer cells of T24 and 5637 were cultured in DMEM and RPMI medium with 10% fetal bovine serum (Gibco, USA) and 1% penicillin-streptomycin (Gibco, USA) at 37[degrees]C in a 5% C[O.sub.2] incubator.

3.6. shRNA and Stable Clones. Short hairpin RNA (shRNA) against NUCB2 (provided by GeneChem, China) was transfected into T24 and 5637 bladder cancer cells using the Lipofectamine 3000 reagent (Invitrogen, USA). To select stable cell clones, cells transfected with shRNA targeting NUCB2 were maintained in medium with 2 [micro]g/ml puromycin for 2 weeks.

3.7. Colony Formation Assays. T24 and 5637 cells were seeded in six-well plates (200 cells/well) at 37[degrees]C in 5% C[O.sub.2] for 2 weeks. Cells were fixed with 100% methanol and stained with 0.1% crystal violet. Pictures were collected using a microscope, and quantitation was acquired using ImagePro Plus 5.0.

3.8. MTT Assay. Cell proliferation and survival were evaluated using the MTT assay [29]. Cells were resuspended in RPMI medium and plated in 200 [micro]l medium at 2000 cells/well in a 96-well plate incubator at 37[degrees]C in 5% C[O.sub.2]. After three days, the medium was removed and 20 [micro]l MTT solution was added into each well at 37[degrees]C for 4 hours. Then, dimethyl sulfoxide (DMSO) was added (150 [micro]l/well) into wells to solubilize the formazan crystals. This plate was incubated at room temperature for 10 min on a shaking table. The results were measured at 570 nm by spectrophotometry.

3.9. Wound Healing Assay. The detailed method refers to the cell migration of the wound healing assay [30]. Briefly, cells transfected with the control plasmid or shRNA were seeded in 6-well plates until cells are confluent. A straight scratch was made using a 200 [micro]l pipette tip, and cells were washed three times using PBS. Cells were incubated for 24 hours at 37[degrees]C in 5% C[O.sub.2], and pictures were collected using a microscope.

3.10. Cell Invasion Assay. For the invasion assay, detailed steps were according to the specification of the reagent (Corning, USA). Briefly, 2 x [10.sup.5] cells were added into the upper transwell chamber of 300 [micro]l no-serum medium with Matrigel while the same number of cells was added into the lower chamber of 500 [micro]l medium with 10% serum for 24 hours at a cell incubator. After 24 hours, cells in the chamber were fixed with methanol for 15 minutes and stained with 0.1% crystal violet. The images were photographed using a microscope, and the results of quantification were calculated by manual counting.

3.11. Animal. Nude BALB/c mice (18-22 g, 6-8 weeks) were provided by Beijing Huafukang Biosciences Co. Inc. T24 bladder cancer cells (5 x [10.sup.6], 100 [micro]l) were injected subcutaneously into the armpit of nude mice. The size of tumors was measured every 7 days, and the tumor volume was calculated using the formula V = 0.5 x L x [W.sup.2], where V is the volume, L is the length, and W is the width. After 49 days, those tumors and lungs were striped, weighted, and photographed.

4. Discussion

To the best of our knowledge, this is the first report of NUCB2 in bladder cancer. Firstly, we indicated that expression of NUCB2 was different in bladder cancer patients and high expression of NUCB2 was associated with poor prognosis. This data suggests that NUCB2 may become a new prognosis marker in bladder cancer.

NUCB2 is widely expressed in the body and participates in several pathophysiological processes, such as appetite and body weight regulation [21, 31, 32] and emotion and stress regulation [23]. In recent years, NUCB2 was found to play an important role in several carcinomas. For studies on NUCB2 in cancers, Fu et al. analyzed a Chinese cohort (training set: 182 patients and validation set: 434 patients) with ccRCC patients and observed through multivariate Cox proportional hazard models that high expression level of NUCB2 was an independent poor prognostic factor for OS and CSS (cancer-specific survival). In ccRCC patients, protein expression level of NUCB2 was associated with the Fuhrman grade [21]. Similarly, Zhang et al. analyzed a cohort containing188 patients with ccRCC and reported that the high expression of NUCB2 had a significant correlation with the PT stage and metastasis [33]. In renal cell carcinoma, Xu et al. observed the novel function of NUCB2 in promoting proliferation and invasion [34]. There were some similar conclusions in prostate cancer. Qetinkaya et al. reported that serum nesfatin-1 level is low in advanced lung cancer patients with weight loss [35]. Those studies could draw a conclusion that high level of NUCB2 was linked to poor prognosis. Our study suggested similar functions of NUCB2 in promoting proliferation, invasion, and migration in bladder cancer. However, there were some opposite reports in other carcinoma which are mainly focused on the female reproductive system. Xu et al. reported that nesfatin-1 inhibited proliferation of HO-8910 cells in vitro by arresting cells at the G1 phase. They found that nesfatin-1 increased apoptosis of HO-8910 and this effect can be blocked by the mTOR and RhoA/ROCK pathway [36]. Ramanjaneya et al. investigated the expression level of nesfatin-1 in H295R cells which are derived from human adrenocortical cells and found that nesfatin-1 promoted apoptosis and inhibited proliferation [27]. It is possible that NUCB2 has high tissue specificity and executes different functions through different signaling pathways.

In order to further study functions of NUCB2 in bladder cancer, T24 and 5637 cells which are derived from human bladder cancer were transfected with special shRNA of NUCB2 to observe phenotypes. The transwell assay, MTT assay, and expression level of MMP2 and MMP9 revealed that knockdown of NUCB2 with special shRNA inhibits invasion and proliferation in bladder cancer cells which were similar to other reports in breast [20], colon [25], and prostate [23] cancer and in clear cell renal cell (ccRCC) carcinoma [21]. The wound healing assay showed that NUCB2 effected migration. In previous researches, NUCB2 was positively associated with Ki-67 which is a marker for the evaluation of cell proliferation in carcinoma [37]. Cell proliferation of bladder cancer was inhibited when transfected with shRNA. The growth of the tumor from the stable clone of NUCB2-knockdown cells was slower than that of cells transfected with control shRNA in vivo. Lung metastases were observed in control T24 cell, but the group of NUCB2-knockdown cells was not. High expression of NUCB2 protein and mRNA was observed in metastases. From the above data, NUCB2 enhanced proliferation, migration, and invasion in vitro and in vivo.

The mechanism of NUCB2 in bladder cancer is still unclear. Kan et al. reported that NUCB2 enhanced invasion, migration, and EMT in colon cancer by LKB1/AMPK/TORC1/ZEB1 pathways [25].

The limitation of this study is the fact that this is a retrospective research with a small number of patient samples in a single center. There were few works on the detailed mechanism on how NUCB2 regulated tumor growth in bladder cancer.

In summary, NUCB2 was identified as a potent marker associated with poor prognosis in bladder cancer by analyzing patient samples, cell lines, and mouse models. These findings may contribute to finding a new target of antitumors in bladder cancer.

Data Availability

The research data used to support the findings of this study are included within the article.

Ethical Approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. All applicable international, national, and/or institutional guidelines for the care and use of animals were followed.

Consent

Informed consent was obtained from all individual participants included in the study.

https://doi.org/10.1155/2018/4272064

Conflicts of Interest

The authors declare that there is no conflict of interest regarding the publication of this paper.

Authors' Contributions

Guang-Ming Liu and Hong-Shun Ma conceived and designed the experiments. Guang-Ming Liu and Zi-Qiang Xu performed the experiments. Guang-Ming Liu, Zi-Qiang Xu, and Hong-Shun Ma contributed reagents/materials/analysis tools. Guang-Ming Liu wrote the paper.

References

[1] D. C. Johnson, P. S. Greene, and M. E. Nielsen, "Surgical advances in bladder cancer: at what cost?," Urologic Clinics of North America, vol. 42, no. 2, pp. 235-252, 2015.

[2] S. Chavan, F. Bray, J. Lortet-Tieulent, M. Goodman, and A. Jemal, "International variations in bladder cancer incidence and mortality," European Urology, vol. 66, no. 1, pp. 59-73, 2014.

[3] S. Antoni, J. Ferlay, I. Soerjomataram, A. Znaor, A. Jemal, and F. Bray, "Bladder cancer incidence and mortality: a global overview and recent trends," European Urology, vol. 71, no. 1, pp. 96-108, 2017.

[4] R. L. Siegel, K. D. Miller, and A. Jemal, "Cancer statistics, 2017, " CA: a Cancer Journal for Clinicians, vol. 67, no. 1, pp. 7-30, 2017.

[5] R. L. Siegel, K. D. Miller, and A. Jemal, "Cancer statistics, 2018, " CA: a Cancer Journal for Clinicians, vol. 68, no. 1, pp. 7-30, 2018.

[6] K.-W. Luo, W.-Y. Lung, C.-X., X.-L. Luo, and W.-R. Huang, "EGCG inhibited bladder cancer T24 and 5637 cell proliferation and migration via PI3K/AKT pathway," Oncotarget, vol. 9, no. 15, pp. 12261-12272, 2018.

[7] X. M. Piao, Y. J. Byun, W. J. Kim, and J. Kim, "Unmasking molecular profiles of bladder cancer," Investigative and Clinical Urology, vol. 59, no. 2, pp. 72-82, 2018.

[8] A. Stengel and Y. Tache, "Role of NUCB2/nesfatin-1 in the hypothalamic control of energy homeostasis," Hormone and Metabolic Research, vol. 45, no. 13, pp. 975-979, 2013.

[9] M. Nakata, D. Gantulga, P. Santoso et al., "Paraventricular NUCB2/nesfatin-1 supports oxytocin and vasopressin neurons to control feeding behavior and fluid balance in male mice," Endocrinology, vol. 157, no. 6, pp. 2322-2332, 2016.

[10] A. Stengel and Y. Tache, "Minireview: nesfatin-1--an emerging new player in the brain-gut, endocrine, and metabolic axis," Endocrinology, vol. 152, no. 11, pp. 4033-4038, 2011.

[11] A. Palasz, M. Krzystanek, J. Worthington et al., "Nesfatin-1, a unique regulatory neuropeptide of the brain," Neuropeptides, vol. 46, no. 3, pp. 105-112, 2012.

[12] Y. Iwasaki, H. Nakabayashi, M. Kakei, H. Shimizu, M. Mori, and T. Yada, "Nesfatin-1 evokes [Ca.sup.2+] signaling in isolated vagal afferent neurons via [Ca.sup.2+] influx through N-type channels," Biochemical and Biophysical Research Communications, vol. 390, no. 3, pp. 958-962, 2009.

[13] S. Oh-I, H. Shimizu, T. Satoh et al., "Identification of nesfatin-1 as a satiety molecule in the hypothalamus," Nature, vol. 443, no. 7112, pp. 709-712, 2006.

[14] C. Ayada, U. Toru, and Y. Korkut, "Nesfatin-1 and its effects on different systems," Hippokratia, vol. 19, no. 1, pp. 4-10, 2015.

[15] C. H. Tang, X. J. Fu, X. L. Xu, X. J. Wei, and H. S. Pan, "The anti-inflammatory and anti-apoptotic effects of nesfatin-1 in the traumatic rat brain," Peptides, vol. 36, no. 1, pp. 39-45, 2012.

[16] S. Ding, W. Qu, S. Dang et al., "Serum nesfatin-1 is reduced in type 2 diabetes mellitus patients with peripheral arterial disease," Medical Science Monitor, vol. 21, pp. 987-991, 2015.

[17] H. Dai, X. Li, T. He et al., "Decreased plasma nesfatin-1 levels in patients with acute myocardial infarction," Peptides, vol. 46, pp. 167-171,2013.

[18] C. Robinson, L. Tsang, A. Solomon et al., "Nesfatin-1 and visfatin expression is associated with reduced atherosclerotic disease risk in patients with rheumatoid arthritis," Peptides, vol. 102, pp. 31-37, 2018.

[19] L. Zeng, J. Zhong, G. He et al., "Identification of nucleobindin-2 as a potential biomarker for breast cancer metastasis using iTRAQ-based quantitative proteomic analysis," Journal of Cancer, vol. 8, no. 15, pp. 3062-3069, 2017.

[20] S. Suzuki, K. Takagi, Y. Miki et al., "Nucleobindin 2 in human breast carcinoma as a potent prognostic factor," Cancer Science, vol. 103, no. 1, pp. 136-143, 2012.

[21] H. Fu, Y. Zhu, Y. Wang et al., "High NUCB2 expression level represents an independent negative prognostic factor in Chinese cohorts of non-metastatic clear cell renal cell carcinoma patients," Oncotarget, vol. 8, no. 21, pp. 35244-35254, 2017.

[22] N. Wang, M. Yao, J. Xu et al., "Autocrine activation of CHRM3 promotes prostate cancer growth and castration resistance via CaM/CaMKK-mediated phosphorylation of Akt," Clinical Cancer Research, vol. 21, no. 20, pp. 4676-4685, 2015.

[23] H. Zhang, C. Qi, A. Wang, L. Li, and Y. Xu, "High expression of nucleobindin 2 mRNA: an independent prognostic factor for overall survival of patients with prostate cancer," Tumor Biology, vol. 35, no. 3, pp. 2025-2028, 2014.

[24] B. Altan, K. Kaira, S. Okada et al., "High expression of nucleobindin 2 is associated with poor prognosis in gastric cancer," Tumour Biology, vol. 39, no. 7, 2017.

[25] J. Y. Kan, M. C. Yen, J. Y. Wang et al., "Nesfatin-1/nucleobindin-2 enhances cell migration, invasion, and epithelial-mesenchymal transition via LKB1/AMPK/TORC1/ZEB1 pathways in colon cancer," Oncotarget, vol. 7, no. 21, pp. 31336-31349, 2016.

[26] K. Takagi, Y. Miki, S. Tanaka et al., "Nucleobindin 2 (NUCB2) in human endometrial carcinoma: a potent prognostic factor associated with cell proliferation and migration," Endocrine Journal, vol. 63, no. 3, pp. 287-299, 2016.

[27] M. Ramanjaneya, B. K. Tan, M. Rucinski et al., "Nesfatin-1 inhibits proliferation and enhances apoptosis of human adrenocortical H295R cells," Journal of Endocrinology, vol. 226, no. 1, pp. 1-11, 2015.

[28] I. Gregersen, M. Skjelland, S. Holm et al., "Increased systemic and local interleukin 9 levels in patients with carotid and coronary atherosclerosis," PLoS One, vol. 8, no. 8, article e72769, 2013.

[29] T. Mosmann, "Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays," Journal of Immunological Methods, vol. 65, no. 1-2, pp. 55-63, 1983.

[30] L. G. Rodriguez, X. Wu, and J.-L. Guan, Cell Migration: Developmental Methods and Protocols, J.-L. Guan, Ed., Humana Press, 2005.

[31] H. Shimizu, M. Tanaka, and A. Osaki, "Transgenic mice overexpressing nesfatin/nucleobindin-2 are susceptible to high-fat diet-induced obesity," Nutrition & Diabetes, vol. 6, no. 3, article e201, 2016.

[32] H. Shimizu and A. Osaki, "Nesfatin/nucleobindin-2 (NUCB2) and glucose homeostasis," Current Hypertension Reviews, vol. 9, no. 4, pp. 270-273, 2014.

[33] H. Zhang, C. Qi, L. Li, F. Luo, and Y. Xu, "Clinical significance of NUCB2 mRNA expression in prostate cancer," Journal of Experimental & Clinical Cancer Research, vol. 32, no. 1, p. 56, 2013.

[34] H. Xu, W. Li, K. Qi, J. Zhou, M. Gu, and Z. Wang, "A novel function of NUCB2 in promoting the development and invasion of renal cell carcinoma," Oncology Letters, vol. 15, no. 2, pp. 2425-2430, 2018.

[35] H. Qetinkaya, B. Karagoz, O. Bilgi et al., "Nesfatin-1 in advanced lung cancer patients with weight loss," Regulatory Peptides, vol. 181, pp. 1-3, 2013.

[36] Y. Xu, X. Pang, M. Dong, F. Wen, and Y. Zhang, "Nesfatin-1 inhibits ovarian epithelial carcinoma cell proliferation in vitro," Biochemical and Biophysical Research Communications, vol. 440, no. 4, pp. 467-472, 2013.

[37] H. Tsujihashi, A. Nakanishi, H. Matsuda, S. Uejima, and T. Kurita, "Cell proliferation of human bladder tumors determined by BrdUrd and Ki-67 immunostaining," The Journal of Urology, vol. 145, no. 4, pp. 846-849, 1991.

Guang-Ming Liu (iD), Zi-Qiang Xu, and Hong-Shun Ma

Department of Urology in Tianjin First Center Hospital, No. 24, Fukang Road, Nankai District Tianjin 300192, China

Correspondence should be addressed to Guang-Ming Liu; brightlgm@126.com

Received 20 May 2018; Revised 27 July 2018; Accepted 5 August 2018; Published 19 September 2018

Academic Editor: Stamatios E. Theocharis

Caption: Figure 1: High expression of NUCB2 was linked to poor prognosis. (a) Representative immunohistochemical images of NUCB2 expression in different patients with bladder cancer. (b) Low IL1A expression intensity in the normal bladder tissues adjacent to carcinoma with IHC was shown. (c) OS and PFS in different NUCB2 expressions.

Caption: Figure 2: NUCB2 knockdown by shRNA in T24 and 5637 cells. (a) Expression level of NUCB2 mRNA in T24 and 5637 cells transfected with shRNA. (b) Western blot shows the NUCB2 level in T24 and 5637 cells transfected with shRNA. Data represent mean [+ or -] SD. * P < 0.05.

Caption: Figure 3: Suppression of NUCB2 inhibits proliferation in the bladder cancer cell line. (a) Colony formation assay using T24 and 5637 cells transfected with shRNA. Left: representative images. Right: quantitative results of the colony formation assay by manual counting. (b) MTT cell proliferation assay of T24 and 5637 cells transfected with shRNA. Results were collected by spectrophotometry at 570 nm. (c) Western blot of Ki-67 in T24 and 5637 cells transfected with shRNA. (d) Western blot of PCNA in T24 and 5637 cells transfected with shRNA. Data represent mean [+ or -] SD. * P < 0.05.

Caption: Figure 4: NUCB2 effected migration and invasion through the MMP2 and MMP9 pathway. (a) Representative images of the wound healing assay and quantitative results of this assay. (b) Cell invasion assay using transwell. Left: representative pictures of the results. Right: quantitative results by counting. (c) Western blot of expression of MMP2. (d) Western blot of expression of MMP9. Data represent mean [+ or -] SD. * P < 0.05.

Caption: Figure 5: Suppression of NUCB2 inhibits tumor growth in mice. T24 cells transfected with NUCB2 shRNA were injected into nude mice to observe growth and metastasis. (a) The T24 cells in vivo stably suppressed NUCB2. The image and growth curve of xenograft tumors were presented. After 49 days, the tumors were stripped. Tumors were measured every 7 days. (b) Representative image of pulmonary metastases in the mouse model and quantitative results of metastases. (c) Western blot and immunohistochemical analysis of expression of NUCB2 in subcutaneous tumors and metastatic tumors. Data were presented as mean [+ or -] SD. * P < 0.05 compared to control group.
Table 1: Relationships of NUCB2 and clinicopathological
characteristics in 115 patients with BC.

Feature                              All            NUCB2
                                  (n = 115)      expression

                                               Low      High
                                              n = 36   n = 79

Age (year)
  <65                                46         18       28
  [greater than or equal to] 65      69         18       51
Gender
  Male                               99         30       69
  Female                             16         6        10
Tumor stage
  T2                                 35         12       23
  T3/T4                              80         24       56
Tumor grade
  Low                                33         13       20
  High                               82         23       59
Lymph node
metastasis
  Yes                                35         8        27
  No                                 80         28       52
Recurrence
  Yes                                59         15       44
  No                                 56         21       35
Distant metastasis
  Yes                                51         10       41
  No                                 64         26       38
Vascular invasion
  Yes                                60         10       50
  No                                 55         26       29

Feature                           [chi square]      P

Age (year)                           2.184        0.139
  <65
  [greater than or equal to] 65
Gender                               0.332        0.565
  Male
  Female
Tumor stage                          0.208        0.648
  T2
  T3/T4
Tumor grade                          1.408        0.235
  Low
  High
Lymph node
metastasis                           1.669        0.196
  Yes
  No
Recurrence                           1.948        0.163
  Yes
  No
Distant metastasis                   5.830       0.016 *
  Yes
  No
Vascular invasion                    12.500      0.000 *
  Yes
  No

* P < 0.05.
COPYRIGHT 2018 Hindawi Limited
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Research Article
Author:Liu, Guang-Ming; Xu, Zi-Qiang; Ma, Hong-Shun
Publication:Disease Markers
Date:Jan 1, 2018
Words:4557
Previous Article:Follistatin-Like 1 Is Downregulated in Morbidly and Super Obese Central-European Population.
Next Article:Application of Lactoferrin and [alpha]1-Antitrypsin in Gingival Retention Fluid to Diagnosis of Periodontal Disease.
Topics:

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters